184473-24-3

Upstream product

• 1264193-11-4 6- bromopyrazolo[1,5-a]pyridine 
• 1345688-05-2 ethyl 6-hydroxypyrazolo[1,5-a]pyridine-7-carboxylate 
• 1345688-04-1 ethyl 2-(5-formyl-1H-pyrazol-1-yl)acetate 
• 76509-17-6 3-benzyloxypyridine 
• 109-00-2 3-HYDROXYPYRIDINE 
• 141032-74-8 6-benzyloxypyrazolo[1,5-a]pyridine-3-carboxylic acid methyl ester 
• 7295-76-3 3-methoxypyridine 
• 1060724-63-1 methyl 6-methoxypyrazolo[1,5-a]pyridine-3-carboxylate 

Downstream Products

• 1060725-30-5 6-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}pyrazolo[1,5-a]pyridine 
• 1060726-14-8 6-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}pyrazolo[1,5-a]pyridine-3-carbaldehyde 

Relevant academic research and scientific papers

BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS

Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R 4, Y1, Y2, n and p are as defined herein.

Functionally selective dopamine D2, D3 receptor partial agonists

Dopamine D2 receptor-promoted activation of Gαo over Gαi may increase synaptic plasticity and thereby might improve negative symptoms of schizophrenia. Heterocyclic dopamine surrogates comprising a pyrazolo[1,5-a]pyridine

[5,6]HETEROCYCLIC COMPOUND

Abstract: An object of the present invention is to provide a novel low molecular weight compound exhibiting an osteogenesis-promoting action. This object is achieved by a compound having the general formula (I) or a pharmacologically acceptable salt thereof. In the general formula (I), R1 and R2 represent hydrogen atoms, and the like; R3 represents a hydrogen atom, and the like; X, Y, and Z represent nitrogen atoms, and the like; A represents a phenylene group, and the like; n represents 1 or 2, and the like; and V and W represent oxygen atoms, and the like.

ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS

The present invention relates to ethynyl compounds of formula wherein X, Y, Z, and R4 are as defined herein or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) and they are therefore useful for the treatment of diseases related to this receptor.

Indolizines and aza-analog derivatives thereof as CNS active compounds

Presently disclosed are indolicine-based compounds of the general formula which have medical utility, for example as antipsychotics.

Synthesis of 1-isopropylamino-3-(pyrazolo[1,5-a]-pyridyloxy)-2-propanols

Treatment of the 4-hydroxypyrazolo[1,5-a]pyridine with glycidyl tosylate in the presence of base, followed by reaction with isopropylamine gave 1-isopropylamino-3-(pyrazolo[1,5-a]pyrid-4-yloxy)-2-propanol. In a similar manner, 1-isopropylamino-3-(pyrazolo[1,5-a]pyrid-6- and 1-isopropylamino-3-(pyrazolo[1,5-a]pyrid-3-yloxy)-2-propanol were also prepared.